The Radionuclide Production and Molecular Radiotherapy Research Laboratories in the Department of Radiation Oncology at the University of Washington (Seattle, WA) develops and evaluates radiochemistry methods that can be applied to produce and purify therapeutic and theranostic radionuclides, as well as radiolabeling reagents/chelators for attaching radionuclides to biological targeting molecules, such as monoclonal antibodies for cancer therapy. The research conducted is primarily funded by the U.S. Department of Energy and the National Institutes of Health. All of the research efforts are collaborative in nature, spanning from therapeutic/theranostic radionuclide production to clinical trials evaluating new radioimmunotherapy agents. The Radionuclide Production and Molecular Radiotherapy Research Laboratories in the Department of Radiation Oncology at the University of Washington (Seattle, WA) is seeking candidates for a postdoctoral scholar research position in radionuclide production for molecular radiotherapy.The Radionuclide Production and Molecular Radiotherapy Research Laboratories in the Department of Radiation Oncology at the University of Washington (Seattle, WA) develops and evaluates radiochemistry methods that can be applied to produce and purify therapeutic and theranostic radionuclides, as well as radiolabeling reagents/chelators for attaching radionuclides to biological targeting molecules, such as monoclonal antibodies for cancer therapy. The research conducted is primarily funded by the U.S. Department of Energy and the National Institutes of Health. All of the research efforts are collaborative in nature, spanning from therapeutic/theranostic radionuclide production to clinical trials evaluating new radioimmunotherapy agents.
The Radionuclide Production and Molecular Radiotherapy Research Laboratories in the Department of Radiation Oncology at the University of Washington (Seattle, WA) is seeking candidates for a postdoctoral scholar research position in radionuclide production for molecular radiotherapy. Our research group develops and evaluates radiochemistry methods that can be applied to produce and purify therapeutic and theranostic radionuclides, as well as development of radiolabeling reagents/chelators used for attaching radionuclides to biological targeting molecules, such as monoclonal antibodies for cancer therapy. Preclinical research in astatine-211-labeled MAbs conducted by our group has been translated to the clinic and is presently being evaluated in multiple human studies.
The University of Washington Medical Cyclotron Facility is capable of producing variable energy proton, deuteron, alpha and high energy neutron beams for radionuclide production. The Postdoctoral Scholar in our research group will collaborate with UW Materials Science research groups and cyclotron engineers to develop new target designs for irradiations. It is planned that the candidate will visit and work with our collaborators at Los Alamos National Laboratory and University of Missouri to develop purification and radiolabeling methods for the production of medical radionuclides. The radiopharmaceuticals under development will be evaluated in animal models through collaborations with investigators in other research groups at the UW and the Fred Hutchinson Cancer Research Center. The initial appointment is one year, with an anticipated start date of August 1, 2020, and the appointment is renewable depending upon performance and availability of funding.
Postdoctoral scholars are represented by UAW 4121 and are subject to the collective bargaining agreement, unless agreed exclusion criteria apply. For more information, please visit the University of Washington https://hr.uw.edu/labor/2019/06/03/agreement-reached-with-uaw-postdoctoral-scholars-on-2019-2021-contract
For more information, please check the announcement below.